文献速递肿瘤 PET/CT

使用[68Ga]Ga-PSMA-11和[18F]PSMA-1007的多参数动态全身PSMA PET/CT

Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007.
PubMed 文献 · EJNMMI Res · 2023-04-15

本研究对20例前列腺癌患者行动态全身PSMA PET/CT,其中10例使用[68Ga]Ga-PSMA-11、10例使用[18F]PSMA-1007,比较两种示踪剂在组织与病灶中的药代动力学,并评估Patlak参数图像的定量能力及对病灶检出和图像可读性的改善。两种示踪剂在器官中动力学明显不同,参数图像视觉质量良好且提高了病灶靶本比,但未检出更多病灶。

要点

  • 两种PSMA示踪剂在器官中动力学明显不同:[68Ga]Ga-PSMA-11为可逆性,[18F]PSMA-1007为不可逆性。
  • 两种示踪剂的病灶动力学均以不可逆模型描述最佳。
  • 参数Ki图像较SUV图像血管信号降低、病灶靶本比增高,但未检出更多恶性病灶。

核心结论

  • 动态全身PET/CT对两种PSMA示踪剂均可行,可直接重建参数Ki图像。
  • 多参数PSMA图像提高了靶本比,但未导致检出更多病灶。
  • 对于定量全身Ki成像,因[18F]PSMA-1007在器官和病灶中呈不可逆动力学,应优先于[68Ga]Ga-PSMA-11使用。

研究设计与样本

  • 研究纳入20例男性前列腺癌患者,采用动态全身PSMA PET协议检查。
  • 10例患者使用[68Ga]Ga-PSMA-11扫描,10例使用[18F]PSMA-1007扫描。
  • 从器官(肝、脾、骨、肌肉)和病灶提取时间-活性曲线进行动力学分析。
  • 每例患者生成三种图像:SUV加Patlak参数图像(Ki和DV)。
  • 对所有图像进行视觉审阅以比较病灶检出,用靶本比量化图像可读性,并比较Ki和DV值。

主要发现

  • 两种PSMA示踪剂在器官中表现出明显不同的药代动力学:[68Ga]Ga-PSMA-11为可逆性,[18F]PSMA-1007为不可逆性。
  • 对于两种示踪剂,病灶动力学均以不可逆模型描述最佳。
  • 使用两种放射性示踪剂时,所有参数图像视觉质量均良好。
  • 总体而言,与SUV图像相比,Ki图像的特征为血管信号降低和病灶靶本比增高。
  • 在参数图像上未识别出额外的恶性病灶。

关键数值与推荐

  • 两种示踪剂在器官中动力学不同:[68Ga]Ga-PSMA-11为可逆性,[18F]PSMA-1007为不可逆性。
  • 两种示踪剂的病灶动力学均以不可逆模型描述最佳。
  • Ki图像较SUV图像血管信号降低、病灶靶本比增高。
  • 参数图像未检出额外恶性病灶。
  • 定量全身Ki成像应优先选用[18F]PSMA-1007而非[68Ga]Ga-PSMA-11。

临床怎么用

  • 动态全身PET/CT可用于两种PSMA示踪剂的参数Ki图像直接重建。
  • 多参数PSMA图像可提高靶本比,但未增加病灶检出。
  • 作者认为,定量全身Ki成像应优先选择[18F]PSMA-1007而非[68Ga]Ga-PSMA-11。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Routine prostate-specific membrane antigen (PSMA) positron emission tomography (PET) performed for primary staging or restaging of prostate cancer patients is usually done as a single static image acquisition 60 min after tracer administration. In this study, we employ dynamic whole-body (D-WB) PET imaging to compare the pharmacokinetics of [68Ga]Ga-PSMA-11 and [18F]PSMA-1007 in various tissues and lesions, and to assess whether Patlak parametric images are quantitative and improve lesion detection and image readability. METHODS: Twenty male patients with prostate cancer were examined using a D-WB PSMA PET protocol. Ten patients were scanned with [68Ga]Ga-PSMA-11 and ten with [18F]PSMA-1007. Kinetic analyses were made using time-activity curves (TACs) extracted from organs (liver, spleen, bone, and muscle) and lesions. For each patient, three images were produced: SUV + Patlak parametric images (Ki and DV). All images were reviewed visually to compare lesion detection, image readability was quantified using target-to-background ratios (TBR), and Ki and DV values were compared. RESULTS: The two PSMA tracers exhibited markedly different pharmacokinetics in organs: reversible for [68Ga]Ga-PSMA-11 and irreversible for [18F]PSMA-1007. For both tracers, lesions kinetics were best described by an irreversible model. All parametric images were of good visual quality using both radiotracers. In general, Ki images were characterized by reduced vascular signal and increased lesion TBR compared with SUV images. No additional malignant lesions were identified on the parametric images. CONCLUSION: D-WB PET/CT is feasible for both PSMA tracers allowing for direct reconstruction of parametric Ki images. The use of multiparametric PSMA images increased TBR but did not lead to the detection of more lesions. For quantitative whole-body Ki imaging, [18F]PSMA-1007 should be preferred over [68Ga]Ga-PSMA-11 due to its irreversible kinetics in organs and lesions.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Dias AH, Jochumsen MR, Zacho HD, et al. Multiparametric dynamic whole-body PSMA PET/CT using [68Ga]Ga-PSMA-11 and [18F]PSMA-1007. EJNMMI Res. 2023. PMID: 37060394. doi:10.1186/s13550-023-00981-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。